Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/
The Centre of Excellence in Long-acting Therapeutics (CELT) at University of Liverpool is a cross-faculty research initiative combining world leading expertise in pharmacology and materials chemistry to provide a better understanding for a range of long-acting technologies, to develop new interventions and harmonise strategies to accelerate long-acting therapeutic development and implementation on a global scale.
CELT’s LONGEVITY project: https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/longevity/
Adult Clinical Trials Group (ACTG) https://actgnetwork.org/
ACTG is the world’s largest HIV clinical trials network focused on curing HIV and reducing the burden of disease and its complications, including tuberculosis and viral hepatitis. ACTG evaluates novel strategies for HIV treatment, including LA/ER formulations. This partnership brings key stakeholders and resources together for discussion, problem solving, and collaboration on joint initiatives.
HIV Prevention Trials Network (HPTN) https://www.hptn.org/
HPTN is a worldwide clinical trials network that develops and tests the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. Part of HPTN’s scientific agenda is to design and conduct studies of long-acting antiretroviral agents and delivery systems for pre-exposure prophylaxis (PrEP) in varied patient populations. LEAP and HPTN collaborate on initiatives and workshops around this shared agenda.
International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) https://www.impaactnetwork.org/
The IMPAACT Network is a global clinical trials network that evaluates interventions to treat and prevent HIV infection and its consequences in infants, children, adolescents and pregnant/postpartum women. A jointly sponsored workshop led to the publication of clear recommendations regarding knowledge gaps and research priorities with regard to long acting antiretroviral products. Other collaborations include the use of modelling and simulation to predict dosing regimens of LA formulations in infants and children.
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) https://atnweb.org/atnweb/
The ATN research program aims to defeat the HIV epidemic among adolescents and young adults in the United States. LEAP and the ATN collaborate on a variety of initiatives related to development and uptake of LA formulations in adolescent populations..
JHU Center for AIDS Research (CFAR) https://www.hopkinscfar.org/
The JHU CFAR and the national CFAR Network aim to enhance and support HIV/AIDS research through mentorship, direct services, and pilot funding. This partnership brings together CFAR investigators focused on LA/ER treatments in HIV and TB with LEAP’s multidisciplinary stakeholders working to facilitate new research partnerships and accelerated development of LA/ER drugs for HIV, TB, and viral hepatitis.
HIV i-Base https://i-base.info/
HIV i-Base is a treatment activist network comprising more than 850 HIV activists in the UK. Founded in 2000, HIV i-base is committed to providing timely and up to date information about HIV treatment to HIV positive people and to healthcare professionals. This partnership ensures community input on LEAP initiatives and advisement on digital communications.
Unitaid is an international organization that invests in innovations to prevent, diagnose, and treat HIV/AIDS, tuberculosis, and malaria more quickly, affordably, and effectively. LEAP partners with Unitaid to assist with maintaining their landscape of HIV treatment and prevention options in long-acting formulations for infectious diseases. This is a joint effort of the WHO and Unitaid
U.S. Food and Drug Administration (FDA) https://www.fda.gov/
FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable. A representative from the FDA is on the LEAP Executive Committee, providing guidance on regulatory, efficacy, and safety issues for LA/ER agents.
Bill and Melinda Gates Foundation https://www.gatesfoundation.org/
One of the Bill and Melina Gates Foundation’s priorities is to accelerate the decline in HIV infection worldwide and save lives by ensuring expanded and simplified HIV treatment and improved and effective use of interventions to prevent new infections. The Foundation has partnered with LEAP to support meetings that expand research partnerships and multidisciplinary discussions for LA/ER formulations.
Clinton Health Access Initiative (CHAI) https://www.clintonhealthaccess.org/
Committed to saving lives and reducing the burden of disease in low-and middle-income countries, CHAI works to strengthen the capabilities of governments and the private sector to create and sustain high-quality health systems that can succeed without our assistance. A CHAI representative is on the LEAP Executive Committee, and the two organizations collaborate in supporting LA/ER formulation development for HIV and related infections.
Medicines Patent Pool (MPP) https://medicinespatentpool.org/
MPP is a United Nations-backed public health organization working to increase access to, and facilitate the development of, life-saving medicines for low-and middle-income countries. As partners, LEAP and MPP explore the feasibility, licensing, and access of LA/ER medicines in LMICs for HIV, TB and Hepatitis B and C.
Treatment Action Group (TAG) https://www.treatmentactiongroup.org/
TAG is a science- and community-based think tank dedicated to the end of HIV/AIDS and its leading co-morbidities, tuberculosis (TB) and hepatitis C virus (HCV). In continued collaboration, LEAP and TAG work together whenever possible to achieve shared goals.